

What Is Claimed Is:

Ins-
a1 1. A method for treating optic and otic infections^{by} parasites and microbes which comprises administering to the site of the infection an effective amount of a protease inhibitor selected from the group consisting of alpha 1-antitrypsin, secretory leucocyte protease inhibitor, anti-plasmin inhibitor and a combination thereof in a suitable pharmaceutically acceptable carrier.

2. The method of claim 1 wherein said protease inhibitor is alpha 1-antitrypsin.

3. The method of claim 1 wherein said microbes comprise pseudomonas.

4. The method of claim 1 wherein said parasites are selected from the group consisting of Shistosoma mansoni and cryptosporidium parvum.

5. The method of claim 1 including a steroid.

6. The method of claim 5 wherein said steroids are selected from the group consisting of dexamethasone, betametasone and triamcinolone acetonide.

7. The method of claim 1 including an antimicrobial effective amount of an antibiotic.

8. The method of claim 7 wherein said antibiotic is anti-pseudomonas.

9. The method of claim 1 including controlling kallikrein and kinin activity.

10. The method of claim 1 including a bradykinin antagonist.

11. The method of claim 1 including hyaluronic acid.

~~12.~~ A method for treating otic infection characterized by elevated pseudomonas and kallikrein activity which comprises administering alpha 1-antitrypsin to the site of infection in a suitable pharmaceutical carrier.

13. The method of claim 12 including an antibiotic.

~~14.~~ A method for treating optic and otic infestation by parasites which comprises administering an effective amount of alpha 1-antitrypsin to the site of infestation in a suitable pharmaceutical carrier.

15. The method of claim 14 including hyaluronic acid.

~~16.~~ A composition for ophthalmologic or otolaryngologic application for patients suffering from parasitic infestation or infections characterized by the presence of pseudomonas and increased kallikrein and kinin activity which comprises:

- A. about 0 to 20 mg. per milliliter of a protease inhibitor selected from the group consisting of alpha 1-antitrypsin, secretory leucocyte protease inhibitor and anti-plasmin inhibitor;
- B. about 0 to 1.5 percent by weight of a steroidal antiphlogistic compound;
- C. about 0 to 5 percent by weight of a non-steroidal antiphlogistic compound;
- D. about 0 to 1.5 percent of hyaluronic acid, in an aqueous pharmaceutically acceptable base.

17. The composition of claim 16 wherein said antiphlogistic

09285740-040699

Ins
Q2

^
a2

composition is anti-pseudomonas.

18. The composition of claim 16 comprising an effective amount of a steroid, and an effective amount of an antibiotic.

19. The composition of claim 18 including an effective amount of hyaluronic acid.

09286740-040699